1,394 results on '"Armstrong, Annalee"'
Search Results
2. Cassava scores a win as FDA declines to intervene in petition to stop its Alzheimer's drug trials
3. Rivus throws down mid-stage liver fat data on quest to climb NASH mountain
4. Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics
5. Completion of Lilly's Alzheimer's submission slips out of Q1 after CMS' Aduhelm decision
6. Arrowhead 'changing horses' for ENaC pulmonary program as phase 1/2 asset shelved
7. Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
8. Anavex touts 'very large' phase 3 win for Rett syndrome drug--2 weeks after moving study's goalposts
9. Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts
10. Provention's med for delaying diabetes wins go-ahead for FDA resubmission
11. With GSK, Alector has the Big Pharma backing to capitalize on a big moment in Alzheimer's drug development
12. Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising
13. CytoDyn board ousts CEO after a wild year, leaving an albatross of a C-suite job to fill
14. Pfizer, BioNTech launch trial for potential omicron-busting vaccine
15. 89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set
16. New clinical trial organization launches with promise to conduct randomized trials at fraction of the cost
17. Does the world need more COVID-19 vaccines? These companies think there's still room for improvement
18. Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water
19. Fierce JPM Week: Game recognizes game--Lilly, Novartis execs commend Pfizer on Paxlovid, but where does that leave them in the COVID market?
20. Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm
21. Fierce JPM Week: As Novartis tries to avoid 'me-too' meds in M&A hunt, R&D chief urges biotechs to 'please reach out'
22. Fierce JPM Week: After 'objectively astonishing' progress on mRNA, biotech looks to tinker with winning formula
23. Eisai takes baton from Biogen as next Alzheimer's prospect follows in Aduhelm's footprints
24. Fierce JPM Week: Pharma reflects on pandemic's 'aha! moments,' which spurred new drive for clinical trial diversity
25. JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker
26. JPM 2022: Editas, which caught flak in 2021 for limited gene editing data, will try to layer on the proof in 2022
27. Intellia stacks ATTR trial with new patient group, will weigh later-stage tweaks after BridgeBio setback
28. JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor
29. JPM 2022: J&J, Legend hope to avoid supply challenges that have ailed Bristol Myers' Abecma as cilta-cel nears FDA nod
30. JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first
31. JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal
32. JPM 2022: Amicus axes gene therapy program for type of Batten disease, advances another
33. JPM 2022: Acadia to Stoke up pipeline with $60M central nervous system research pact
34. JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal
35. JPM 2022: Pfizer locks in 2 partners to solidify status as mRNA powerhouse
36. JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks
37. Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway
38. Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room for hepatitis C drug
39. Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
40. With Alnylam in rear view, John Maraganore wants to be a biotech multiplier, matchmaker and mentor
41. Aligos says stop right now to lead hep B med after fruitless phase 1 data
42. Annexon shares dip 30% as patient dropouts dog midphase Huntington's trial
43. Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues
44. Merck KGaA takes 4th option on Big Pharma darling F-star's bispecific immunotherapies
45. Pfizer, BioNTech team up again, taking a swing at GSK's Shingrix dominance
46. Biogen, Ionis see no need to change the formula for Spinraza successor
47. Johnson & Johnson ships another bispecific off to FDA, this time in multiple myeloma
48. AstraZeneca taps Ionis to join crowd of companies gunning for rare heart disease in deal worth billions in biobucks
49. Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
50. Editor's Corner: Fierce Biotech's top 10 most read stories in 2021
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.